CCIA
INBX

Campbell & Co Investment Adviser’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,516
Closed -$894K – 1430
2023
Q4 		$894K Buy
+23,516
New +$504K 0.08% 436

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Campbell & Co Investment Adviser's INBX Position: Q1 2024 in Review

Campbell & Co Investment Adviser sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 23,516 shares — an estimated $894K sold.

Campbell & Co Investment Adviser first reported a position in INBX in Q4 2023 and held it in 1 quarter. The position peaked at $894K in Q4 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Campbell & Co Investment Adviser reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 23,516 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $894K.
  • Campbell & Co Investment Adviser first reported a position in Inhibrx, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Inhibrx, Inc. Common Stock position peaked at $894K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2024, filed 10 May 2024.